Specialty Pharmacy

Behind The Script is a photo submission campaign designed to feature real pharmacists with candid, HIPAA-compliant photos to celebrate American Pharmacist Month.

In this interview for World Standards Week, Nakia Eldridge, PharmD, MPH, of US Pharmacopeia (USP), discusses USP's key achievements in 2024, while outlining the organization's 2025 goals.

The lawsuit alleges that the action was taken without the required notice and disputes the agency’s warning of “localized supply disruption,” while calling for more transparency.

Offering pharmacy professionals insights into the benefits, importance and challenges associated with switching patients to long-acting injectables to treat schizophrenia.

This approval marks the first and only anti-tissue factor pathway inhibitor approved in the US for the treatment hemophilia A or B, and the first approved hemophilia treatment to be administered via a pre-filled, auto-injector pen.

Results are promising, particularly because they represent the second clinical trial of a GLP-1 receptor agonist showing potential benefits for PD motor symptoms

The exemption allows more time for partners to adhere to enhanced distribution security requirements in the Food, Drug, & Cosmetics Act and prevents possible supply chain disruptions.

Ambulatory infusion centers can help reduce the cost of care for payers and patients and allow pharmacists to contribute to a positive treatment experience.

The regulatory action is based on a positive preliminary analysis of the VANTAGE trial.

Despite its importance, after graduating from pharmacy school, many pharmacists likely experience a decline in confidence in their ability to appropriately evaluate studies and interpret statistical findings.

The analysis assessed the feasibility of autologous transplantation of chemically-induced pluripotent stem cell-derived islets for type 1 diabetes.

Formularies have become one of the biggest barriers to realizing the cost-saving potential of biosimilars.

When considering the 3-stage framework, perhaps a greater emphasis on pre-treatment phase research could help identify some of the more individual traits used to better predict patient outcomes.

The treatment aims to reduce prolonged QTc interval in patients with long QT syndrome.

Currently, Danon disease has a poor prognosis and does not have any pharmaceutical therapeutics for treatment or management.

As American Pharmacists Month begins, Alan Corley talks the importance of pharmacists and the value of the profession personally and to the overall community.

In May 2024, the first biosimilars for aflibercept were approved, which included aflibercept-jbvf (Yesafili; Biocon Biologics), known as MYL-1701P.

Positive trial results laid the groundwork for the designation.

Treatment for primary coenzyme Q10 (CoQ10) deficiency can include high-dose oral CoQ10 supplementation, but not all patients respond to this treatment.

Ustekinumab is a human monoclonal antibody targeting the cytokines interleukin (IL)-12 and IL-23, which play a rule in the inflammatory and immune responses.

MDL-101 is a proposed novel precision medicine that targets the LAMA1 gene, causing LAMA2 congenital muscular dystrophy type 1a.

Alan Corley, pharmacy owner in Greenville, TN, reflects on the changes he's witnessed throughout his career and the most rewarding aspects of his profession.

Xanomeline and trospium chloride is the first in a new class, offering a new approach with selectively targeting M1 and M4 receptors.

In adolescents, a comprehensive model using behavioral and MRI data had a prediction accuracy of 0.83, which was higher than single data type models.

The discontinuation comes after a review of the medication by the European Medicines Agency which found that “the total number of deaths was higher than anticipated.”

Treatment is typically tailored to the individuals, with HCT being the only curative treatment bone marrow failure, but long-term outcomes are generally poorer due to toxicities.

Additional education can address ambivalence for patients and providers, which can start at the pharmacist level, as they are essential sources of information for patients.

As the end of the DSCSA stabilization period approaches, Josh Bolin from the NABP provides an overview of what to expect.

The authors note this is the first study to assess cerebrovascular endothelial extracellular vesicles within a cognitive condition.

Three of the largest pharmacy benefit managers ––Express Scripts, Optum, and Caremark––are listed in the suit.